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Micelles: Chemotherapeutic Drug Delivery
Antoine Al-Achi1* and Jonathan Lawrence BS2
Micelles have become one of the main players in nanoparticle 
research. Although micelles have been around for decades, it was not 
until recently that these particles were finally utilized in advanced 
drug delivery systems. Micelles formation is an efficient method for 
delivering poorly water-soluble drugs [1], and its usefulness is in 
particular applicable to chemotherapeutic agents [2]. Polymer-based 
micelles have been the main focus of researchers in the past several 
years. Cancer has unique characteristics that can be exploited for drug 
delivery. Tumor vasculature specifically has become a burgeoning area 
of research over the past few decades. The enhanced permeability and 
retention effect (EPR) in solid tumors is one of the main reasons that 
polymeric micelles are able to selectively distribute to tumor cells as 
opposed to normal tissues [3]. Bradykinin, nitric oxide, peroxynitrite, 
and VEGF are vascular permeability factors found to be elevated in the 
tumor environment which enhances angiogenesis [4]. Collagenases 
also help induce vascular permeability by causing disintegration of 
matrix tissue surrounding blood vessels [4]. Fenestrations in regular 
vessels are too small for penetration of nanoparticles, compared to 
those as large as 600-800 nm in tumor tissue [3]. Therefore, polymeric 
micelles are able to penetrate tumor tissue selectively, achieve 
higher concentrations, and have a longer duration of action than 
regular dosage forms, subsequently requiring less dosing. Regular 
body processes also play a role in drug permeability and retention. 
The reticuloendothelial system (RES), comprised of monocytes and 
macrophages, is responsible “for engulfing and clearing old cells, 
miscellaneous cellular debris, foreign substances, and pathogens 
from the bloodstream” [5]. Polymeric micelles are able to effectively 
avoid opsonization by the RES and achieve longer circulation times. 
Longer circulation times again allow enhanced permeability to tissues 
resulting in a greater therapeutic response. 
Understanding micelle structure is a key to realizing their potential 
as novel drug delivery systems. Micelles are surfactant molecules, 
which aggregate in aqueous or oily liquids [4]; the micelles occupy 
the dispersed phase of a colloidal system [6]. Amphipathic monomers, 
each containing a hydrophilic and hydrophobic domain, make up a 
polymeric micelle. Micelle’s ability to aggregate and carry drugs is 
conferred by a property known as the critical micelle concentration 
(CMC). These amphipathic monomers do not aggregate until the 
CMC is reached, at which time spontaneous aggregation occurs 
resulting in polymeric micelles. CMC values for nanoparticles are 
generally much lower than most commercially available products (on 
the order of 10-6 or 10-7); if the micelles faced dilution, (i.e., injection 
into the body) then a drop in concentration below the CMC would 
cause loss of structural integrity. The CMC phenomenon is due 
to the dehydration of the hydrophobic tails, leading to a favorable 
state of entropy [4]. The hydrophobic domains comprise the micelle 
“core” while the hydrophilic domains make up the micelle exterior 
or “corona” [3]. Hydrophobic cores are ideal for encapsulating 
hydrophobic drugs, which is where most research has been focused 
and has found success. Formation of van der Waals bonds between 
the hydrophobic polymer core and drug help stabilize the micelle. 
The hydrophilic corona also helps stabilize the micelle structure due 
to the formation of hydrogen bonds with the surrounding aqueous 
solution [4]. Encapsulation of hydrophilic drugs has been attempted, 
but currently has been unsuccessful and needs to be studied further. 
The entire complex of micelle and drug can then vary in size from 
ten to hundreds of nanometers; although, nanoparticles under 100 
nm seem to fair the best in vivo. So how would someone realistically 
create these compounds? There are several popular methods of 
nanoparticle synthesis which will be highlighted: emulsification-
solvent evaporation, solvent displacement, and salting out. 
Emulsification-solvent evaporation usually utilizes a simple 
emulsion (w/o) or double emulsion (w/o/w) technique. Simple 
emulsions are used mainly for hydrophobic drugs. Like most 
stabile emulsions, sufficient shear is needed to disperse the aqueous 
phase in the organic solvent. Dichloromethane, ethyl alcohol, and 
other volatile solvents immiscible with water are used commonly 
as organic solvents, while drugs mixed with the chosen polymer 
occupy the dispersed phase. The dispersed phase must also contain 
appropriate levels of surfactant (sodium cholate, poly-vinyl alcohol, 
etc) to form micelles with the drug molecules. In order to provide 
the necessary amount of shear, complex methods of mixing, such 
as homogenization or probe sonication are employed. Micelles are 
collected by centrifugation after mixing, the solvent is removed by 
evaporation, and the final product is distributed in water. A double 
emulsion is formed similarly; however, when the primary emulsion 
(w/o) is formed with the drug and organic solvent, this emulsion is 
then dispersed throughout another aqueous phase (w/o/w). Double 
emulsions are useful for encapsulating hydrophilic drugs [7].
Solvent Displacement, also known as nanoprecipitation or solvent 
diffusion, was first described by Fessi et al. (1989) [8]. In this method, 
solvents miscible with water are used (acetone, etc). The drug, polymer, 
and surfactants are dispersed throughout the organic phase. “A 
submicron o/w emulsion is spontaneously formed due to immediate 
reduction of the interfacial tension with rapid diffusion of acetone 
into the aqueous phase (the Marangoni effect)” [7]. The final steps are 
similar to the emulsification-solvent evaporation method; however, 
solvent displacement is not used to encapsulate water-soluble drugs. 
Advantageously, lesser shear is required in this method [7].
The salting out method can be used to encapsulate hydrophobic 
drugs only. A primary o/w emulsion is formed with the drug and 
polymer in the organic phase. “As salting out agents can be used 
electrolytes, such as magnesium chloride, sodium chloride, or 
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magnesium acetate and non-electrolytes, such as sucrose” [7]. The 
main purpose of the salting out agent is to make a usually water-
soluble solvent such as acetone insoluble by supersaturating the 
solution. Acetone diffusion into the aqueous phase then causes the 
formation of nanoparticles [9].
Synthesis of the polymeric micelle is a tricky task itself. However, 
once formed, micelles must achieve the proper therapeutic effect, last 
for a desired amount of time, and be eliminated with ease without any 
complications. As knowledge of micelle structure and kinetics grows, 
drug delivery utilizing polymeric micelles will become smarter. The 
basis of any drug’s structure is its inherent components and size. 
Polymer-based micelles, specifically A-B co-block polymers, have 
gained much attention recently. In this structure the A segment is 
hydrophilic and the B segment is hydrophobic. Polyethylene glycol 
is the most commonly used hydrophilic segment because it is a FDA 
approved nontoxic polymer [3]. Poly(lactide-co-glycolide)(PLGA) is 
the most commonly used hydrophobic segment in research. However, 
many other compounds or variations can and have been used. An 
increase in the internal/external phase ratio leads to a slight decrease 
of the nanoparticle’s average size, whereas a nanoparticle size increase 
was observed when the polymer/surfactant ratio was higher [9].
The preparation of nanoparticles via emulsion based techniques 
requires the use of compounds to stabilize the formulation. Poly(vinyl 
alcohol)(PVA) and human serum albumin (HSA) have been used 
effectively as stabilizers in Doxorubicin-loaded PLGA nanoparticles. 
PVA seems to be more effective; however, Lecithin has been used to 
increase the activity of HAS and found to be better than PVA [10]. 
Nanoparticle size appears to decrease with increases in stabilizer 
concentration between 0.5 and 5% w/v [9]. In order to make sure 
adequate levels of drug are being delivered inside nanoparticles, 
one must study several parameters: Nanoparticle recovery (%) and 
encapsulation efficiency, which is broken down into drug content 
(drug loading, % w/w) and drug entrapment (%). Changing the 
aqueous phase pH from 5.8 to 9.3 increased procaine hydrochloride 
nanoparticle recovery from 65.1 to 93.4%, drug content from 
0.3 to 1.3% (w/w), and drug entrapment from 11.0 to 58.2% [11]. 
Poly(styrene-co-maleic acid)(SMA)-tanespimycin micelles were 
reported with a loading efficiency of 93%, while an even higher 
loading efficiency with Paclitaxel nanoparticles of 96% was seen 
[12,13]. The loading efficiency of Paclitaxel nanoparticles was found 
to be decreased when the external aqueous phase volume was doubled 
(nanoprecipitation method). The method of preparation of the 
organic phase may also influence the loading efficiency [14]. Some 
strives have been made to simulate the compatibility of drugs with 
certain co-block polymers. In one example with PEO-b-PCL block 
copolymers, Flory-Huggins interaction parameters were found to be 
more consistent with experimental solubility data than the traditional 
group contribution method used in the pharmaceutical industry 
[15]. Regardless of the design, it is important to note that high 
nanoparticle recovery is required for reducing manufacturing costs. 
High entrapment efficiency will reduce the amount of carrier needed 
for the administration to the target site and help eliminate wastage 
during manufacturing.
Other studies have examined the possibility of multiple drug 
carriers. It is well known that chemotherapy regimens using multiple 
drugs will enhance tumor inhibition. For example, common 
acronyms such as TAC, CMF, or TCH denote combination therapies 
for breast cancer [16]. Beyond inhibiting tumor growth, combination 
nanoparticle drugs will allow better dosage optimization and 
convenience. Unimers of Doxorubicin and Camptothecin conjugated 
to poly-L-lactide (PLA) can be controlled ratiometrically with over 
90% loading efficiency. This control is achieved simply by adjusting 
the DOX-PLA:CPT-PLA molar ratio. This dual drug combination was 
proven to exhibit more cellular cytotoxicity than single drug-loaded 
nanoparticles [17]. Nanoparticles co-loaded with Doxorubicin and 
Paclitaxel in a concentration ratio of 2:1 showed high anti-tumor 
activity against three different types of tumor cells [18]. Again, these 
co-loaded nanoparticles were found to be superior to single drug 
formulations. A 3-in-1 injection of Poly(ethylene glycol)-block-
poly(D,L-lactic acid)(PEG-b-PLA) micelles carrying the three anti-
cancer drugs Paclitaxel, 17-allyamino-17demethoxygeldanamycin, 
and rapamycin reduced tumor volume by 1.6 fold [19].
Once ready to be administered, micelles are injected and enter 
cells by endocytosis. Drug targeting to specific cells can be specialized 
through ligand-receptor interactions. Octreotide conjugated micelles 
carrying Docetaxel were found to be a viable option for delivery to 
tumor cells over expressing the somatostatin receptor. This receptor 
is found over-expressed in many types of tumors such as prostate and 
breast cancer and regulates inhibition of hormone and growth factor 
secretion [20]. A ligand for Melanocortin 1 receptor, a ligand over-
expressed in melanomas, was found to bind effectively and selectively 
while conjugated to micelles. However, some loss of affinity was noted 
when small peptides were attached to larger micelles [21]. Integrin-
ανβ3 receptor, over-expressed in angiogenic tumor blood vessels, can 
be targeted using Arg-Gly-Asp (RGD); Folic acid can also be used to 
target the folate receptor over-expressed in many breast, lung, kidney, 
and brain cancers. An increase in uptake of RGD and folic acid 
conjugated nanoparticles to HUVEC and KB cells respectively was 
seen. Uptake was modulated by increasing or decreasing the density 
of the ligands on the nanoparticle surface [22]. Micelles modified 
with anti-nucleosome monoclonal antibody 2C5 demonstrated 
higher cytotoxicity in tumor cells than free drug against the B16 
(murine melanoma) and 4T1 (murine mammary carcinoma) cell 
lines [23]. AS1411 is a DNA aptamer that specifically binds nucleolin, 
which is highly expressed in cancer cells and endothelial cells lining 
angiogenic blood vessels. Nanoparticles conjugated with AS1411 and 
carrying Paclitaxel enhanced uptake and thus tumor inhibition in C6 
glioma cells. Entry of micelles into the cell has been explored by these 
methods and others as well; however, once inside, triggers exist to 
potentially obtain even better drug targeting.
Multiple methods of activation have been studied for nanoparticle 
release including: pH, temperature, ultrasound, light, and chemical 
reactions. One interesting example utilizes polymers conjugated 
to histidine and phenylalanine. These poly(L-histidine-co-L-
phenylalanine) polymers are blended with poly(L-lactic acid)-b-PEG-
folate (PLLA-b-PEG-folate) polymers in order to create a micelle that 
targets early endosomal pH (roughly pH 6). The histidine moiety, with 
a pKa of around 6.5, transitions from hydrophobic properties at high 
pH, (>7.0) to hydrophilic properties at low pH (<7.0) due to ionization 
of the imidazole group at lower pH. However, the histidine conjugated 
polymers must be conjugated with phenylalanine moieties and then 
blended with PLLA-b-PEG-folate polymers in order to: i) create a drug 
effective against multi-drug resistant (MDR) tumors and ii) allow 
the micelle structure to maintain shape at physiological pH (pH 7.4) 
and still release drug at the tumor site when engulfed by endosomes 
(pH 6) [24]. Micelles synthesized with poly(N-isopropylacrylamide) 
(PNIPAAm) have a thermosensitive property that allows them 
to maintain stability at 37° Celsius and deform at 39.5° Celsius to 
release Doxorubicin [25]. Doxorubicin loaded micelles also were 
shown to enter cells and be released effectively by ultrasound. Yield 
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of intraperitoneal ovarian carcinoma tumors decreased from 70% for 
Doxorubicin to 36% for the same concentration of Doxorubicin loaded 
micelles with a 30 second sonication. This effect was independent of 
temperature, because of its occurrence at low ultrasound energies, 
well below that used for hyperthermia tumor treatment. The effect is 
thought to be related to ultrasound’s ability to cause cell membrane 
disruption, resulting in a transient increase in cell membrane 
permeability of the tumor interstitial environment [26]. Micelle 
polymers conjugated with photochromic spiropyran (SP) units 
undergo reversible isomerization between colorless SP and colored 
merocyanine (ME). Irradiation with UV light (365 nm) completely 
disrupted the micelles, while irradiation with visible light (620 nm) 
effectively reversed the dissociation. This delivery system was used to 
carry the hydrophobic dye coumarin 102 [27]. Novel mechanisms will 
enable increased drug specificity for tumor tissue.
Once micelles are triggered, then how would we characterize their 
release profile? It has been well-documented that most polymeric 
micelles exhibit a biphasic release profile. Micelles containing 
procaine hydrochloride exhibited immediate release of about 65% 
over 15 minutes followed by release of the remaining drug over 
4-6 hours [11]. Micelles containing Paclitaxel were found to release 
roughly 30% of the drug after 12 hours, followed by sustained release 
of roughly 65% of the drug over 72 hours [14]. Tanespimycin release 
from micelles occurred at 51% and 95% over 2 and 8 hours, respectively 
[12]. Sustained release was noted with release of Tamoxifen citrate 
from micelles conjugated with guar gum. Here it was noted that the 
predominant mechanism behind drug release was time dependent 
release and diffusion [28]. However, this is consistent with theories 
given by other researchers reporting biphasic release profiles, since it 
is believed that the initial rapid release is caused by drug adsorbed or 
close to the surface of the nanoparticles and large surface to volume 
ratio, while the sustained release may be due to diffusion of the drug 
from the core [11]. Biphasic release would be desirable since a drug’s 
effect would then be immediate and long-lasting. Overall, it appears 
that the biphasic release characteristics of micelle systems vary with 
its composition. This would lead one to believe that desirable release 
characteristics could be achieved simply by changing these molecules. 
Contributions in this field could lead to a need for less dosing or 
reduced toxicity.
So what are some practical, in vivo applications of micelle systems? 
There are several FDA approved compounds that are currently in use 
for certain types of cancer. However, given the amount of research on 
micelles, FDA approved compounds remain relatively few: Genexol-
PM, Oncaspar, and Abraxane. Published data associated with micelle 
toxicity is slim, probably due to the fact that there is a penchant to 
publish positive results. In addition, due to the increased specificity 
for target tissues, nanoparticles are less likely to cause systemic side 
effects. Toxic substances used in conventional drug delivery may 
become unnecessary if micelles dosage form is used instead. For 
example, an excipient in the formulation of Paclitaxel, Cremophor 
EL, has been associated with severe hypersensitivity reactions. 
Preparation of nanoparticles without Cremophor EL has been shown 
to reduce these undesirable reactions.
Micelles appear to have some role in delivering chemotherapeutic 
agents in an efficient and targeted way. However, complexity of 
preparation and stability remain issues of concern regarding this 
dosage form.
References
1. Saha SC, Patel D, Rahman S, Savva M (2013) Physicochemical 
characterization, solubilization, and stabilization of 9-nitrocamptothecin 
using pluronic block copolymers. J Pharm Sci 102: 3653-3665.
2. Qiu JF, Gao X, Wang BL, Wei XW, Gou ML, et al. (2013) Preparation 
and characterization of monomethoxy poly(ethylene glycol)-poly(Îµ-
caprolactone) micelles for the solubilization and in vivo delivery of luteolin. Int 
J Nanomedicine 8: 3061-3069.
3. Mohanty C, Acharya S, Sahoo S (2010) Micelles: The Multifunctional 
Nanocarrier for Colloidal Drug Delivery. In Colloids in Drug Delivery.CRC 
Press, Taylor and Francis Group, USA. 
4. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular 
permeability and the EPR effect in macromolecular therapeutics: a review. J 
Control Release 65: 271-284.
5. Adams ML, Lavasanifar A, Kwon GS (2003) Amphiphilic block copolymers for 
drug delivery. J Pharm Sci 92: 1343-1355.
6. Torchilin VP (2007) Micellar nanocarriers: pharmaceutical perspectives. 
Pharm Res 24: 1-16.
7. Avgoustakis K (2004) Pegylated poly(lactide) and poly(lactide-co-glycolide) 
nanoparticles: preparation, properties and possible applications in drug 
delivery. Curr Drug Deliv 1: 321-333.
8. Fessi H, Puisieux F, Devissaguet JPh, Ammoury N, Benita S (1989) 
Nanocapsule formation by interfacial polymer deposition following solvent 
displacement. International Journal of Pharmaceutics 55: R1-R4. 
9. Quintanar-Guerrero D, Fessi H, Allemann E, Doelker E (1996) Influence of 
stabilizing agents and preparative variables on the formation of poly(D,L-lactic 
acid) nanoparticles by an emulsification-diffusion technique. International 
Journal of Pharmaceutics 143: 133-141. 
10. Wohlfart S, Khalansky AS, Gelperina S, Maksimenko O, Bernreuther C, et al. 
(2011) Efficient chemotherapy of rate glioblastoma using Doxorubicin-loaded 
PLGA nanoparticles with different stabilizers. PLoS One 6: e19121. 
11. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS (1999) PLGA 
nanoparticles prepared by nanoprecipitation: drug loading and release 
studies of a water soluble drug. J Control Release 57: 171-185. 
12. Larson N, Greish K, Bauer H, Maeda H, Ghandehari H (2011) Synthesis 
and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the 
delivery of tanespimycin. Int J Pharm 420: 111-117.
13. Liang C, Yang Y, Ling Y, Huang Y, Li T, et al. (2011) Improved therapeutic effect 
of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. 
Bioorg Med Chem 19: 4057-4066.
14. Fonseca C, Simões S, Gaspar R (2002) Paclitaxel-loaded PLGA 
nanoparticles: preparation, physiochemical characterization and in vitro anti-
tumoral activity. J Control Release 83: 273-286. 
15. Patel S, Lavasanifar A, Choi P (2008) Application of molecular dynamics 
simulation to predict the compatibility between water-insoluble drugs and self-
associating poly(ethylene oxide)-b-poly(eta-caprolactone) block copolymers. 
Biomacromolecules 9: 3014-3023. 
16. Susan G Komen (2013) Chemotherapy Drugs.
17. Aryal S, Hu CM, Zhang L (2011) Polymeric nanoparticles with precise 
ratiometric control over drug loading for combination therapy. Mol Pharm 8: 
1401-1407.
18. Wang H, Zhao Y, Wu Y, Hu YL, Nan K, et al. (2011) Enhanced anti-tumor 
efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy 
PEG-PLGA copolymer nanoparticles. Biomaterials 32: 8281-8290.
19. Cho H, Kwon GS (2011) Polymeric micelles for neoadjuvant cancer therapy 
and tumor-primed optical imaging. ACS Nano 5: 8721-8729.
20. Zhang Y, Wang X, Wang J, Zhang X, Zhang Q (2011) Octreotide-modified 
polymeric micelles as potential carriers for targeted Docetaxel delivery to 
somatostatin receptor overexpressing tumor cells. Pharm Res 28: 1167-1178.
21. Barkey NM, Tafreshi NK, Josan JS, De Silva CR, Sill KN, et al. (2011) 
Development of melanoma-targeted polymer micelles by conjugation of a 
melanocortin 1 receptor (MC1R) specific ligand. J Med Chem 54: 8078-8084. 
22. Valencia PM, Hanewich-Hollatz MH, Gao W, Karim F, Langer R, et al. (2011) 
Effects of ligands with different water solubilities on self-assembly and 
properties of targeted nanoparticles. Biomaterials 32: 6226-6233. 
23. Sawant RR, Sawant RM, Torchilin VP (2008) Mixed PEG-PE/vitamin E 
Citation: Al-Achi A, Jonathan Lawrence BS (2013) Micelles: Chemotherapeutic Drug Delivery. Clinic Pharmacol Biopharmaceut 2: e114. 
doi:10.4172/2167-065X.1000e114
Page 4 of 4
Volume 2 • Issue 2 • 1000e114Clinic Pharmacol BiopharmaceutISSN: 2167-065X  CPB an open access journal 
tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer 
drugs: improved drug solubilization and enhanced in vitro cytotoxicity. Eur J 
Pharm Biopharm 70: 51-57. 
24. Kim D, Gao ZG, Lee ES, Bae YH (2009) In vivo evaluation of doxorubicin-
loaded polymeric micelles targeting folate receptors and early endosomal pH 
in drug-resistant ovarian cancer. Mol Pharm 6: 1353-1362.
25. Liu SQ, Tong YW, Yang YY (2005) Incorporation and in vitro release
of doxorubicin in thermally sensitive micelles made from poly(N-
isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-
glycolide) with varying compositions. Biomaterials 26: 5064-5074.
26. Gao ZG, Fain HD, Rapoport N (2005) Controlled and targeted tumor
chemotherapy by micellar-encapsulated drug and ultrasound. J Control
Release 102: 203-222.
27. Lee HI, Wu W, Oh JK, Mueller L, Sherwood G, et al. (2007) Light-induced
reversible formation of polymeric micelles. Angew Chem Int Ed Engl 46:
2453-2457. 
28. Sarmah JK, Mahanta R, Bhattacharjee SK, Mahanta R, Biswas A (2011)
Controlled release of tamoxifen citrate encapsulated in cross-linked guar
gum nanoparticles. Int J Biol Macromol 49: 390-396. 
